Algen AstraZeneca partnership aims to enhance AI-driven drug discovery, focusing on chronic inflammatory conditions for innovative solutions.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
Galapagos cell therapy sale decision expected soon as company reviews limited proposals from financial investors.
Genmab Merus acquisition for $8 billion enhances its oncology portfolio with innovative therapies like Petosemtamab.
Glenmark Hengrui licensing deal secures $1 billion, granting exclusive rights and impacting the pharmaceutical market.
Pfizer Metsera acquisition enhances its obesity drug portfolio with promising GLP-1 and amylin candidates for $4.9 billion.
Biogen Alcyone acquisition grants access to implantable device, potentially easing RNA drug delivery for treatments like Spinraza.
Arvinas out-license vepdegestrant with Pfizer, impacting their partnership and market strategy.
Roche 89bio deal involves a $2.4 billion acquisition, targeting MASH with a late-stage drug that could impact the market significantly.
AbbVie acquires bretisilocin for up to $1.2 billion, marking a significant move in psychedelic treatments.
Novartis Monte Rosa partnership focuses on immunology, potentially worth $5.7 billion.